PORTON PHARMA SOLUTIONS LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.98 CNY | +2.10% |
|
+2.47% | -32.49% |
| Sales 2023 * | 3.87B 534M | Sales 2024 * | 3.88B 536M | Capitalization | 9.27B 1.28B |
|---|---|---|---|---|---|
| Net income 2023 * | 446M 61.55M | Net income 2024 * | 445M 61.41M | EV / Sales 2023 * | 2.4 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 2.39 x |
| P/E ratio 2023 * |
20.8
x | P/E ratio 2024 * |
20.8
x | Employees | 5,263 |
| Yield 2023 * |
1.32% | Yield 2024 * |
1.25% | Free-Float | 56.08% |
More Fundamentals
* Assessed data
More news
| 1 day | +2.10% | ||
| 1 week | +2.47% | ||
| Current month | -5.14% | ||
| 1 month | -10.82% | ||
| 3 months | -19.79% | ||
| 6 months | -34.97% | ||
| Current year | -32.49% |
1 week
15.85
17.03
1 month
15.8518.87
Current year
14.7125.25
1 year
14.7134.84
3 years
14.71109.77
5 years
7.45109.77
10 years
7.04109.77
| Managers | Title | Age | Since |
|---|---|---|---|
Nian Feng Ju
CEO | Chief Executive Officer | 52 | 10-12-31 |
Hui Chen
DFI | Director of Finance/CFO | 45 | 22-04-21 |
Yong Qing Tan
CHM | Chairman | 69 | 19-04-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Gang Yuan
BRD | Director/Board Member | 57 | 21-08-04 |
Nian Feng Ju
CEO | Chief Executive Officer | 52 | 10-12-31 |
Hui Zeng
BRD | Director/Board Member | 44 | 10-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 16.98 | +2.10% | 7 794 401 |
| 24-04-25 | 16.63 | +1.59% | 6,761,063 |
| 24-04-24 | 16.37 | -0.37% | 4,610,417 |
| 24-04-23 | 16.43 | +0.98% | 5,589,259 |
| 24-04-22 | 16.27 | +0.74% | 4,853,219 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Porton Pharma Solutions Ltd., formerly Porton Fine Chemicals Ltd., is a China-based company principally engaged in the provision of customized pharmaceutical research and production services. The Company is also engaged in the multi-client product manufacturing businesses and pharmaceutical and chemical commerce businesses. The products of the Company include anti-viral, anti-diabetic, hypolipidemic, anti-cancer, anesthesia analgesia and anti-bacterial pharmaceuticals, among others. The Company operates its businesses in Europe, North America, Asia and China, among others.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
16.63
CNY
Average target price
28.5
CNY
Spread / Average Target
+71.38%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.49% | 1.25B | |
| +26.13% | 653B | |
| +27.00% | 556B | |
| -6.56% | 354B | |
| +20.53% | 331B | |
| +3.13% | 296B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.20% | 144B |
- Stock Market
- Equities
- 300363 Stock
